Jennifer Anne Treiberg

USPTO Granted Patents = 43 (Patent Applications = 16)

CIPO Patents = 7 (Patent Applications = 6)

EPO Patents = 18 (Patent Applications = 14)

Average Co-Inventor Count = 8.0

ph-index = 17

Forward Citations = 1,273(Granted Patents)

Location History:

Bothell, WA (US) (2003 - 2014)
Redmond, WA (US) (2011 - 2024)

Company Filing History:

Gilead Sciences, Inc.

Years Active: 2003-2025

Loading Chart...

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459922 - PARP7 inhibitors (2025-11-04),

2. 12240862 - Inhibitors of peptidylarginine deiminases (2025-03-04),

3. 12053462 - Quinoline derivatives (2024-08-06),

4. 11976083 - Inhibitors of peptidylarginine deiminases (2024-05-07),

5. 11224600 - Compounds for inhibition of alpha 4 beta 7 integrin (2022-01-18),

6. 11179383 - Compounds for inhibition of α4β7 integrin (2021-11-23),

7. 11174256 - Imidazopyridine derivatives (2021-11-16),

8. 11116760 - Quinoline derivatives (2021-09-14),

9. 11021467 - Phosphatidylinositol 3-kinase inhibitors (2021-06-01),

10. 10906907 - Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof (2021-02-02),

11. 10695349 - Inhibitors of human phosphatidylinositol 3-kinase delta (2020-06-30),

12. 10479770 - Phosphatidylinositol 3-kinase inhibitors (2019-11-19),

13. 10398695 - Inhibitors of human phosphatidylinositol 3-kinase delta (2019-09-03),

14. 10336756 - (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta (2019-07-02),

15. 10308639 - Phosphatidylinositol 3-kinase inhibitors (2019-06-04),

Title: The Inventor Spotlight: Jennifer Anne Treiberg

Introduction:

Jennifer Anne Treiberg is a prolific inventor based in Redmond, WA, with an impressive track record of 39 patents to her name. Her innovative work in the field of pharmaceuticals has been making waves in the industry, particularly in the realm of treating inflammatory diseases.

Latest Patents:

Treiberg's latest patents showcase her prowess in developing compounds for the inhibition of alpha 4 beta 7 integrin. These compounds, along with their pharmaceutically acceptable salts, have paved the way for new pharmaceutical compositions and therapeutic methods in the treatment of inflammatory diseases.

Career Highlights:

Throughout her career, Treiberg has made significant contributions to renowned companies such as Icos Corporation and Gilead Sciences, Inc. Her insights and inventions have played a crucial role in advancing the pharmaceutical industry and improving healthcare outcomes for patients worldwide.

Collaborations:

Treiberg has collaborated with esteemed professionals in the field, including Edward A Kesicki and Amy Oliver. Together, they have worked on groundbreaking projects that have pushed the boundaries of innovation and research in pharmaceuticals.

Conclusion:

Jennifer Anne Treiberg's remarkable journey as an inventor underscores her dedication to pushing the boundaries of scientific discovery. Her trailblazing work in developing compounds for treating inflammatory diseases has cemented her reputation as a visionary in the field. With 39 patents under her belt and a string of successful collaborations, Treiberg continues to inspire and drive innovation in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.